Wednesday, March 29, 2023
Astellas Pharma announced that it has entered into an agreement with Roche Diabetes Care for the development and commercialisation of Roche Diabetes Care's world-renowned Accu-Chek® Guide Me blood glucose monitoring system with advanced accuracy as a combined medical product with BlueStar®*. BlueStar is an FDA-cleared digital health solution for diabetes patients, developed by Welldoc.
Astellas, Roche Diabetes Care, and Welldoc aim to provide new treatment options and contribute to patients suffering from diabetes by developing Roche Diabetes Care's Accu-Chek® Guide Me blood glucose monitoring system as a combined medical product with BlueStar® in Japan. This partnership with Astellas, aims to bring a new standard of care in diabetes to a broader population in Asia.
The combined medical product solution, which is being developed in Japan, is expected to support patients with managing their diabetes by capturing, storing, and transmitting blood glucose data which is obtained from Roche Diabetes Care's Accu-Chek® Guide Me system and track medication, diet, activity and exercise in Welldoc’s BlueStar(app). It is also expected to support patients’ diabetes self-management with a unique algorithm designed using AI, and personalised digital coaching messages, focused on building better habits over time.
